Complete response and overall survival–univariate analyses for all patients (N = 1317)
| Factor . | n . | CR . | Survival . | ||
|---|---|---|---|---|---|
| n (%) . | P* . | Weeks . | P† . | ||
| Diagnosis to treatment interval, d | |||||
| 1 | 178 | 123 (69) | 50.0 | ||
| 2 | 178 | 118 (66) | 49.0 | ||
| 3 | 179 | 119 (66) | 51.0 | ||
| 4 | 161 | 98 (61) | 58.0 | ||
| 5-6 | 188 | 112 (60) | 48.0 | ||
| 7-10 | 221 | 123 (56) | 47.0 | ||
| > 10 | 212 | 108 (51) | < .001 | 39.0 | .16 |
| Treated as a continuous variable‡ | < .001 | .04 | |||
| WBC, per mm3 | |||||
| < 1.5 | 205 | 123 (60) | 52.0 | ||
| 1.5-< 2.5 | 203 | 130 (64) | 49.0 | ||
| 2.5-< 4.0 | 186 | 115 (62) | 49.0 | ||
| 4.0-< 8.0 | 217 | 140 (65) | 52.0 | ||
| 8.0-< 14.0 | 172 | 95 (55) | 36.0 | ||
| 14.0-< 25.0 | 162 | 98 (60) | 53.0 | ||
| ≥ 25.0 | 172 | 100 (58) | .33 | 43.0 | .88 |
| Treated as a continuous variable‡ | .34 | .41 | |||
| Etiology | |||||
| De novo | 728 | 500 (69) | 59.0 | ||
| Secondary | 589 | 301 (51) | < .001 | 38.0 | < .001 |
| Performance status | |||||
| 0 | 163 | 106 (65) | 90.0 | ||
| 1 | 710 | 443 (62) | 50.0 | ||
| 2 | 195 | 94 (48) | 26.0 | ||
| 3-4 | 54 | 20 (37) | < .001 | 5.0 | < .001 |
| Cytogenetics | |||||
| Favorable | 105 | 98 (93) | N/A | ||
| Intermediate | 874 | 572 (65) | 60.0 | ||
| Unfavorable | 338 | 131 (39) | < .001 | 19.0 | < .001 |
| Cytarabine dose | |||||
| Conventional | 260 | 175 (67) | 56.0 | ||
| Mid-dose CI | 490 | 284 (58) | 45.0 | ||
| Mid- to high-dose bolus | 562 | 340 (61) | .16 | 49.0 | .32 |
| Factor . | n . | CR . | Survival . | ||
|---|---|---|---|---|---|
| n (%) . | P* . | Weeks . | P† . | ||
| Diagnosis to treatment interval, d | |||||
| 1 | 178 | 123 (69) | 50.0 | ||
| 2 | 178 | 118 (66) | 49.0 | ||
| 3 | 179 | 119 (66) | 51.0 | ||
| 4 | 161 | 98 (61) | 58.0 | ||
| 5-6 | 188 | 112 (60) | 48.0 | ||
| 7-10 | 221 | 123 (56) | 47.0 | ||
| > 10 | 212 | 108 (51) | < .001 | 39.0 | .16 |
| Treated as a continuous variable‡ | < .001 | .04 | |||
| WBC, per mm3 | |||||
| < 1.5 | 205 | 123 (60) | 52.0 | ||
| 1.5-< 2.5 | 203 | 130 (64) | 49.0 | ||
| 2.5-< 4.0 | 186 | 115 (62) | 49.0 | ||
| 4.0-< 8.0 | 217 | 140 (65) | 52.0 | ||
| 8.0-< 14.0 | 172 | 95 (55) | 36.0 | ||
| 14.0-< 25.0 | 162 | 98 (60) | 53.0 | ||
| ≥ 25.0 | 172 | 100 (58) | .33 | 43.0 | .88 |
| Treated as a continuous variable‡ | .34 | .41 | |||
| Etiology | |||||
| De novo | 728 | 500 (69) | 59.0 | ||
| Secondary | 589 | 301 (51) | < .001 | 38.0 | < .001 |
| Performance status | |||||
| 0 | 163 | 106 (65) | 90.0 | ||
| 1 | 710 | 443 (62) | 50.0 | ||
| 2 | 195 | 94 (48) | 26.0 | ||
| 3-4 | 54 | 20 (37) | < .001 | 5.0 | < .001 |
| Cytogenetics | |||||
| Favorable | 105 | 98 (93) | N/A | ||
| Intermediate | 874 | 572 (65) | 60.0 | ||
| Unfavorable | 338 | 131 (39) | < .001 | 19.0 | < .001 |
| Cytarabine dose | |||||
| Conventional | 260 | 175 (67) | 56.0 | ||
| Mid-dose CI | 490 | 284 (58) | 45.0 | ||
| Mid- to high-dose bolus | 562 | 340 (61) | .16 | 49.0 | .32 |
NA indicates not applicable.
χ2 test for factors with 2 levels, Cochran-Armitage trend test if more than 2 levels.
Log-rank test for factors with 2 levels, log-logistic model if more than 2 levels.
P values are from logistic (CR) and log-logistic (survival) models using the original, untransformed data.